ENTITY
InnoCare Pharma

InnoCare Pharma (9969 HK)

120
Analysis
Health Care • China
InnoCare Pharma is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing drugs for cancer and autoimmune diseases. Its pipeline includes key products like orelabrutinib, tafasitamab, and ICP-332. The company was co-founded in 2015 and is headquartered in Beijing, China.
more
bullish•Kangji Medical
•16 Aug 2020 17:17

HSCI Index Rebalance - Stock Connect Flows Coming Up

The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....

Logo
722 Views
Share
bullish•CanSino Biologics
•22 Jul 2020 05:39

HSCI and Stock Connect - Biotech Stocks Now Eligible; Inclusion & Exclusion Possibilities

Hang Seng Indexes Company (HSIL) reviews the constituents of the Hang Seng Composite Index (HSCI) on a half yearly basis in March and September...

Logo
1.1k Views
Share
bullish•Alibaba
•15 Jul 2020 12:47

HK IPO Analytics 1H2020: Highlight of Brokers' and Sectors' Performance, and Insti Book Color

As we regularly analyse deal performance, it is time to look at how the HK IPO markets performed during the first half of 2020. In this note, we...

Logo
609 Views
Share
bullish•Ocumension
•09 Jul 2020 13:29

Ocumension Therapeutics IPO: Trading Debut

Ocumension Therapeutics (1477 HK) is a China-based ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing...

Logo
544 Views
Share
•06 Jun 2020 04:07

HKEx (388.HK): Trading Volume in May Points to Upside and New License Agreement with MSCI

HKEX (388 HK) just released its May market statistics. The May month ADT (Average Daily Turnover) has registered 14% month-to-month rebound to HKD...

Logo
Roger Xie
582 Views
Share
x